<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David R Holmes, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nikolaus Sarafoff, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephan Windecker, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald Cutlip, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H442449880">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients who undergo percutaneous coronary intervention (PCI) are at risk of periprocedural bleeding, a complication that results from the combination of vascular puncture and periprocedural antithrombotic therapy, the latter of which generally includes
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , a P2Y
         <sub>
          12
         </sub>
         receptor blocker, and a parenteral anticoagulant. This bleeding risk is further increased in any patient receiving chronic anticoagulant therapy. Approximately 5 percent of patients undergoing PCI are treated with long-term oral anticoagulation (OAC) for conditions such as atrial fibrillation, venous thromboembolism, or prior placement of a mechanical heart valve [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">
          "Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Cardiac catheterization'
         </a>
         .)
        </p>
        <p>
         The optimal periprocedural antithrombotic strategy in these patients depends on the relative risks of thrombosis in patients who have their anticoagulant temporarily stopped and bleeding risk if it is continued. These risks are also impacted by whether the patient is undergoing an elective or urgent procedure (eg, acute coronary syndrome).
        </p>
        <p>
         This topic discusses issues surrounding the periprocedural management of antithrombotic therapy in patients on OAC undergoing PCI. The issues surrounding the care of patients who are candidates for longer-term dual antiplatelet therapy and anticoagulant therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">
          "Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3412803265">
         <span class="h1">
          DEFINING THE ISSUES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of periprocedural antithrombotic therapy in patients undergoing percutaneous coronary intervention (PCI) is challenging because of the competing risks of thrombosis and bleeding. Interrupting anticoagulation for this procedure transiently increases the risk of periprocedural thromboembolism while continuing anticoagulant therapy may increase the risk of periprocedural bleeding. In addition, if the patient has a bleeding complication, the anticoagulant is often discontinued for a variable length of time, resulting in a longer period of increased thromboembolic risk. (See
         <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">
          "Periprocedural bleeding in patients undergoing percutaneous coronary intervention"
         </a>
         .)
        </p>
        <p>
         It is estimated that 5 to 10 percent of patients referred for PCI have a strong indication for long-term anticoagulation, with atrial fibrillation (AF) being the most common [
         <a href="#rid3">
          3-7
         </a>
         ].
        </p>
        <p>
         The following are pivotal questions in these patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Does the need for long-term oral anticoagulation change the choice and timing of oral antiplatelet regimen? (See
         <a class="local">
          'Dual antiplatelet therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Can oral anticoagulant therapy be interrupted? This has major implications in patients receiving anticoagulants for prosthetic heart valves. In most of these specific patients with prosthetic valves requiring urgent PCI, it cannot be interrupted. (See
         <a class="local">
          'Preprocedural anticoagulant management'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">
          "Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Cardiac catheterization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If interrupted, is preprocedural heparin bridging needed? (See
         <a class="local">
          'Preprocedural anticoagulant management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is intraprocedural heparin needed and if so, at what dose? (See
         <a class="local">
          'Intraprocedural anticoagulant management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When should the first dose of oral anticoagulant be given after an uncomplicated procedure? (See
         <a class="local">
          'Postprocedural anticoagulant management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1599907900">
         <span class="h2">
          Bleeding risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no validated method for estimating the risks of bleeding in this setting. The HAS-BLED score is able to assess the bleeding risk in patients with AF who receive oral anticoagulation (OAC). However, in patients with PCI who receive dual antiplatelet therapy, the HAS-BLED score does not predict major bleeding events and in patients with PCI and AF, a modified HAS-BLED score is also unable to predict bleeding events [
         <a href="#rid8">
          8-10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/108359.html" rel="external">
          "High bleeding risk patients undergoing percutaneous coronary intervention", section on 'Assessing individual patient risk'
         </a>
         .)
        </p>
        <p>
         Risk factors for bleeding include older age, female sex, low body weight use of the femoral artery for access (compared with the radial artery), age greater than 75 years, and baseline comorbidities such as anemia and chronic kidney disease.
        </p>
        <p class="headingAnchor" id="H2854520216">
         <span class="h2">
          Thrombotic (ischemic) risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients at relatively low thrombotic risk include patients with older deep vein thrombosis or atrial fibrillation with lower CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score. Those at relatively high or very high thrombotic risk include individuals with a mechanical mitral valve or high CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score  (
         <a class="graphic graphic_table graphicRef86930" href="/z/d/graphic/86930.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2119553542">
         <span class="h1">
          DUAL ANTIPLATELET THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most anticoagulated patients undergoing percutaneous coronary intervention (PCI) will require one week to one month of triple antithrombotic therapy with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , a P2Y
         <sub>
          12
         </sub>
         receptor blocker, and an oral anticoagulant (OAC). The combination of aspirin and a P2Y
         <sub>
          12
         </sub>
         receptor blocker is referred to as dual antiplatelet therapy (DAPT); aspirin plus
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         is our preferred combination for patients receiving OAC in the first weeks after PCI. (See
         <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">
          "Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         should be started as soon as the diagnosis of coronary artery disease is made. For patients not previously taking aspirin, we load with 162 to 325 mg and treat with 81 to 100 mg daily. The need for chronic OAC does not change the dose or timing of aspirin. (See
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         For most patients who will require some period of combined anticoagulant and antithrombotic therapy, we prefer
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         to one of the more potent P2Y
         <sub>
          12
         </sub>
         receptor blockers (
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         or
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         ), including patients who are being treated for an acute coronary syndrome. This recommendation is based on the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The randomized trials of DAPT in stable patients used
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         rather than more potent P2Y
         <sub>
          12
         </sub>
         receptor blockers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is an increase in the baseline bleeding risk in individuals taking OAC therapy and DAPT. Thus, even in acute coronary syndrome patients who would ordinarily receive a more potent P2Y
         <sub>
          12
         </sub>
         receptor blocker, we prefer
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">
          "Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Bleeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95.html" rel="external">
          "Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Invasive management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94.html" rel="external">
          "Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving primary PCI'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Exceptions include those who are allergic to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and those with prior stent thrombosis while taking clopidogrel. In patients who are considered for triple therapy, typically in most clinical practices,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         is used only for the shortest period of time (some people would say only one week), and then the patient is continued on clopidogrel and the oral anticoagulant.
        </p>
        <p>
         The timing and dose of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients undergoing urgent PCI, we load with 600 mg at the time of diagnosis and continue 75 mg daily. In patients who present with an acute coronary syndrome while taking
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , we typically reload with either 300 or 600 mg. (See
         <a class="medical medical_review" href="/z/d/html/94.html" rel="external">
          "Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'P2Y12 use'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95.html" rel="external">
          "Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'P2Y12 use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For stable patients whose coronary anatomy is not known and who are scheduled for diagnostic coronary angiography with possible PCI, we suggest withholding
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (600 mg loading dose) until after diagnostic coronary angiography, as many patients will either not have disease that needs revascularization or will have disease that requires coronary artery bypass surgery. Patients with prior diagnostic coronary angiography who are scheduled for PCI should receive clopidogrel (600 mg loading dose) at least two hours before PCI. (See
         <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'P2Y12 receptor blockers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         There are limited data on the role of newer P2Y
         <sub>
          12
         </sub>
         inhibitors as part of triple therapy. In a prospective observational study of 377 patients who underwent drug-eluting stent placement and who had an indication for OAC, 5.6 percent received
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         and the rest
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         [
         <a href="#rid11">
          11
         </a>
         ]. All patients were treated with triple therapy for at least six months. The primary end point of Thrombolysis In Myocardial Infarction major and minor bleeding occurred more often in the prasugrel group (28.6 versus 6.7 percent; adjusted hazard ratio [HR] 3.2, 95% CI 1.1-9.1). There was no significant difference in the composite secondary end point (death, myocardial infarction [MI], ischemic stroke, or definite stent thrombosis). In this study, in most patients, the indication for prasugrel was high platelet reactivity on clopidogrel. (See
         <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">
          "Clopidogrel resistance and clopidogrel treatment failure", section on 'Definitions'
         </a>
         .)
        </p>
        <p>
         In the RE-DUAL PCI trial, 2725 OAC patients who underwent DES placement were randomized to
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         110 or 150 mg with P2Y12 inhibitor (
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         or
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ), or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         with P2Y12 inhibitor (ticagrelor or clopidogrel) and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         . In the group of patients treated with ticagrelor, the study treatment-independent incidence of the first ISTH major or clinically relevant nonmajor bleeding event was 26.3 percent, and in those treated with clopidogrel 20.1 percent (multivariable adjusted HR 1.35; 95% CI 1.05-1.72) [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1895234107">
         <span class="h1">
          PREPROCEDURAL ANTICOAGULANT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients, we do not attempt to reverse (either with a reversal agent or by letting the anticoagulant effect wear off) the anticoagulant effect of the long-term anticoagulant prior to percutaneous coronary intervention (PCI). Arterial access using the radial artery significantly lowers the risk of access site bleeding and is part of the rationale for not reversing oral anticoagulation (OAC). (See
         <a class="local">
          'Access site'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3696164203">
         <span class="h2">
          Urgent patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients taking long-term OAC who require urgent or emergent PCI, there is generally not sufficient time to stop the OAC (and its anticoagulant effect). By default, management decisions move to the periprocedural period. (See
         <a class="local">
          'Intraprocedural anticoagulant management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3197873219">
         <span class="h2">
          Elective patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients, we assess the relative risk of periprocedural bleeding if anticoagulant is continued and thrombosis if it is withheld. Bleeding risk is discussed above. (See
         <a class="local">
          'Bleeding risk'
         </a>
         above.)
        </p>
        <p>
         After considering the thrombosis and bleeding risks, we hold anticoagulant therapy only for those with a low thrombotic risk and high bleeding risk. For most patients taking direct-acting oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]; eg,
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         ,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         , or
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         ), we do not attempt to reverse the anticoagulant effect with newer reversal agents. For most patients taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , we do not routinely reverse its effect with
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         or fresh frozen plasma because with the former, reinitiation of warfarin is more difficult with uneven variation in INR until a stable level of warfarin has been reached.
        </p>
        <p>
         In addition to the comments below, the management of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         prior to PCI is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">
          "Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"
         </a>
         .)
        </p>
        <p>
         The following are guidelines for when to administer the last preprocedural anticoagulant dose:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For elective patients taking DOACs, we continue therapy until 24 hours before the procedure. In patients with renal insufficiency, we give the last dose 36 to 48 hours before the procedure, particularly with
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         . A detailed discussion of when to stop DOACs is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants", section on 'Timing of anticoagulant interruption'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When DOACs are temporarily paused, there is no need for bridging with low molecular weight heparin/
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         . No study has shown a reduction in periprocedural thrombotic or embolic cardiovascular events with heparin bridging and at least two studies have shown an increase in periprocedural bleeding [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , we measure the international normalized ratio (INR) in advance (at least two days) of the procedure. We make adjustments to the warfarin dose to allow the INR to be at the lower end of the target range (2.0 to 2.5) the morning of the procedure. If it is anticipated that a large sheath will be placed in the femoral artery, we may hold warfarin for longer and allow the INR to fall below 2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In most cases we do not bridge with heparin even if the INR falls below 2. Exceptions include those with very high thrombotic risk such as mechanical heart valves, particularly in the mitral position or older aortic mechanical valves, those atrial fibrillation patients with a CHA2DS2-VASc score &gt;5, patients with recent ischemic stroke within three months, or recent venous thromboembolism within three months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our recommendations regarding the preprocedural management of OAC in patients referred for elective PCI are based on observations only; randomized trials or high-quality observational studies are not available. Our approach to performing PCI without
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         interruption (but at the lower end of the therapeutic INR level) is based on evidence obtained in other populations [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The BRUISE CONTROL trial randomly assigned patients on
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         undergoing implantation of a cardiac implantable electronic device to continuation of warfarin or heparin bridging [
         <a href="#rid16">
          16
         </a>
         ]. This trial found a lower risk of bleeding in patients who continued warfarin. (See
         <a class="medical medical_review" href="/z/d/html/108919.html" rel="external">
          "Cardiac implantable electronic devices: Periprocedural complications", section on 'Bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A benefit of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         continuation rather than discontinuation with bridging was reported in the COMPARE trial, which randomly assigned patients with atrial fibrillation undergoing catheter ablation to continued warfarin or discontinuation of warfarin with bridging. In this trial, patients assigned to the warfarin group had a lower risk of stroke and less bleeding. (See
         <a class="medical medical_review" href="/z/d/html/94502.html" rel="external">
          "Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation", section on 'Patients taking long-term vitamin K antagonist'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2010 meta-analysis of eight moderate- to low-quality studies of patients undergoing elective coronary angiography with or without PCI found that a strategy of uninterrupted
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         antagonist lowered the risk of access site bleeding by approximately 50 percent, compared with interrupted vitamin K antagonist [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1004710073">
         <span class="h1">
          INTRAPROCEDURAL ANTICOAGULANT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to preprocedural issues, intraprocedural decisions regarding antithrombotic therapy have not been well studied in patients taking long-term oral anticoagulant (OAC).
        </p>
        <p class="headingAnchor" id="H1978180351">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are the sequential steps we take to optimize antithrombotic care during the procedure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As the risk of bleeding at the catheterization site is significantly lower with the use of the radial artery, we prefer it to the femoral artery if possible in most patients. (See
         <a class="local">
          'Access site'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">
          "Periprocedural complications of percutaneous coronary intervention", section on 'Radial artery access'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">
          "Percutaneous arterial access techniques for diagnostic or interventional procedures", section on 'Radial artery'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We give intraprocedural
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         to most patients, irrespective of whether the long-term anticoagulant is
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         or a direct-acting oral anticoagulant (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]). We acknowledge that there is some (weak) evidence to suggest that heparin may be omitted in patients taking therapeutic dose of warfarin [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/93.html" rel="external">
          "Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Anticoagulant Use'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Heparin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/92.html" rel="external">
          "Acute ST-elevation myocardial infarction: Management of anticoagulation", section on 'Primary percutaneous coronary intervention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the international normalized ratio (INR) is &lt;2, we given full dose heparin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , we reduce the normal heparin dose if the INR is &gt;2 and &lt;2.5, we use reduced doses of heparin, and we typically keep the activated clotting time on the low side (200 to 225).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We prefer to delay elective PCI if the INR is &gt;2.5. For patients with an INR &gt;2.5 who must have PCI that day, we reduce the dose of heparin even further.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of glycoprotein (GP) IIb/IIIa inhibitors should be minimized. (See
         <a class="local">
          'Use of GP IIb/IIIa inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3141680425">
         <span class="h2">
          Access site
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients undergoing PCI, access using the radial rather than the femoral artery decreases the risk of periprocedural bleeding. As patients receiving OAC therapy are at particularly high bleeding risk, we prefer radial access in most cases if possible. This issue is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">
          "Periprocedural bleeding in patients undergoing percutaneous coronary intervention", section on 'Access site'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">
          "Periprocedural complications of percutaneous coronary intervention", section on 'Radial artery access'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">
          "Percutaneous arterial access techniques for diagnostic or interventional procedures", section on 'Radial artery'
         </a>
         .)
        </p>
        <p>
         If a transradial approach is not an option, we strongly recommend using a micropuncture technique and ultrasound guidance. The use of a femoral vascular closure device (VCD) in patients on oral anticoagulation has shown that VCDs reduced the occurrence of pseudoaneurysms and time to hemostasis [
         <a href="#rid19">
          19
         </a>
         ]. We choose the smallest diameter femoral sheath possible.
        </p>
        <p class="headingAnchor" id="H2694330659">
         <span class="h2">
          Stent type
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most anticoagulated patients undergoing PCI, we recommend newer-generation drug-eluting stents (DES) rather than bare metal stents (BMS) based on their superiority with regard to the rate of restenosis and their lower rate of stent thrombosis in many circumstances. (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1772896071">
         <span class="h2">
          Use of GP IIb/IIIa inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some patients undergoing PCI, antiplatelet therapy with intravenous GP IIb/IIIa inhibitors may be beneficial. (See
         <a class="medical medical_review" href="/z/d/html/94.html" rel="external">
          "Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Summary and recommendations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'GP IIb/IIIa inhibitors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95.html" rel="external">
          "Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Invasive management'
         </a>
         .)
        </p>
        <p>
         However, due to the higher bleeding risk in patients who receive this class of antiplatelet therapy, we are very restrictive of their use in patients with concomitant OAC. We limit the use of these agents in our patients to those with a suboptimal angiographic result or those with a very high-risk lesions (large thrombotic burden in patients who have not received adequate
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         load in time prior to the procedure).
        </p>
        <p class="headingAnchor" id="H1544178550">
         <span class="h1">
          POSTPROCEDURAL ANTICOAGULANT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be reassessed for their need for chronic anticoagulation prior to reinitiation. This should include consideration of other approaches that could be used to avoid the need for long-term anticoagulation such as left atrial appendage occlusion. For patients in whom oral anticoagulant (OAC) will be restarted, and assuming no significant postprocedural bleeding has occurred, the next major decision is when to restart OAC.
        </p>
        <p>
         The optimal time to restart anticoagulant therapy after percutaneous coronary intervention (PCI) is not known. For most patients, the goal is to restart anticoagulation as soon as possible after PCI. In the absence of evidence to support one approach or another, we suggest the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who did not take their OAC the morning of the PCI, we restart OAC therapy the evening after the procedure in patients without evidence of bleeding, particularly if they have undergone radial artery access.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients treated with a femoral artery approach, it is reasonable to restart a newer OAC the morning following the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients at very high risk of thrombosis (eg, mechanical heart valves, high CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score) who are taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , we continue therapeutic heparin after the procedure until the international normalized ratio (INR) is therapeutic. The INR should be monitored closely, particularly in the first four weeks after discharge (high-risk period for hemorrhage). This is particularly important for the uncommon patient in whom
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         was administered as it affects the INR for some time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the presence of significant, ongoing postprocedural bleeding, we delay initiation of OAC therapy. Similar to all patients, the timing of initiation must take  into account the benefits and risks of doing so.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If significant bleeding occurs after the procedure and the patient’s INR on
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         before the procedure was &gt;2, the use of fresh frozen plasma may be an option. (See
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4185907466">
         <span class="h1">
          PERIPROCEDURAL BLEEDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         If active bleeding is present or develops, or the international normalized ratio on
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         is very high, we consider using
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         or fresh frozen plasma. This issue is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">
          "Periprocedural bleeding in patients undergoing percutaneous coronary intervention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H442449953">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Major societal guidelines do not address the issue of how to manage patients taking oral anticoagulant therapy who are referred for percutaneous coronary intervention in any detail.
        </p>
        <p>
         Our recommendations are generally consistent with those made in the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, and the 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with nonvalvular atrial fibrillation [
         <a href="#rid20">
          20-22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1270893483">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">
          "Society guideline links: Anticoagulation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119297.html" rel="external">
          "Society guideline links: Percutaneous coronary intervention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H442449946">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Defining the issues
         </strong>
         – In patients who undergo percutaneous coronary intervention (PCI) with stenting, chronic oral anticoagulant (OAC) therapy, when added to dual antiplatelet therapy, increases the risk of periprocedural bleeding. Our recommendations for managing this increase in risk follow. (See
         <a class="local">
          'Defining the issues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach in stable patients
         </strong>
         – For stable patients, we recommend
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         rather any other P2Y
         <sub>
          12
         </sub>
         receptor blocker (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). For patients with acute coronary syndrome, we recommend clopidogrel rather any other P2Y
         <sub>
          12
         </sub>
         receptor blocker (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). (See
         <a class="local">
          'Dual antiplatelet therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are taking
         </strong>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         <strong>
         </strong>
         – For patients taking warfarin, we measure the international normalized ratio (INR) in advance (at least two days) of the procedure. We make adjustments to the warfarin dose to allow the INR to be at the lower end of the target range the morning of the procedure. If it is anticipated that a large sheath will be placed in the femoral artery, we may hold warfarin for longer and allow the INR to fall below 2. We suggest this method rather than allowing return of normal clotting status (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Preprocedural anticoagulant management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In most cases, we do not bridge with heparin even if the INR falls below 2. Exceptions include those with very high thrombotic risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are taking direct-acting oral anticoagulant
         </strong>
         – For patients receiving a direct-acting oral anticoagulant (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]), we stop the last dose about 24 hours before the procedure in elective cases rather than stopping sooner (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intraprocedural anticoagulation
         </strong>
         – We give intraprocedural heparin to most patients. For patients taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , we reduce the normal heparin dose if the INR is &gt;2 and reduce it further if it is &gt;2.5. (See
         <a class="local">
          'Intraprocedural anticoagulant management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We prefer the radial access in most cases, as it decreases the risk of periprocedural bleeding. If the femoral access has been chosen, we encourage the use of micro-puncture technique closure devices. (See
         <a class="local">
          'Access site'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Periprocedural timing
         </strong>
         – The timing of restarting OAC depends on factors such as risk of thrombosis off anticoagulant, access site used, and the timing of the last dose of anticoagulant prior to the procedure. For patients who did not take their OAC the morning of the PCI, we restart OAC therapy the evening after the procedure in patients without evidence of bleeding, particularly if they have undergone radial artery access. (See
         <a class="local">
          'Postprocedural anticoagulant management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schömig A, Sarafoff N, Seyfarth M. Triple antithrombotic management after stent implantation: when and how? Heart 2009; 95:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes DR Jr, Kereiakes DJ, Kleiman NS, et al. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009; 54:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hylek EM, Solarz DE. Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. JACC Cardiovasc Interv 2008; 1:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubboli A, Colletta M, Valencia J, et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 2009; 22:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang TY, Robinson LA, Ou FS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 2008; 155:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Nodar JM, Marín F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capodanno D, Rossini R, Musumeci G, et al. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Int J Cardiol 2015; 199:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puurunen MK, Kiviniemi T, Schlitt A, et al. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thromb Res 2014; 133:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61:2060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J 2019; 40:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35:1888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sticherling C, Marin F, Birnie D, et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015; 17:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368:2084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamula E, Lloyd NS, Schwalm JD, et al. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis. Chest 2010; 138:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiviniemi T, Karjalainen P, Pietilä M, et al. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. Am J Cardiol 2012; 110:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer K, Gewalt S, Morath T, et al. Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture in Patients on Oral Anticoagulation - Post Hoc Analysis of the ISAR-CLOSURE Trial. J Invasive Cardiol 2021; 33:E709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145:e4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021; 23:1612.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 101552 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19605755" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Triple antithrombotic management after stent implantation: when and how?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19573725" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Combining antiplatelet and anticoagulant therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19393146" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17267456" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19453820" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18215609" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18294566" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299623" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26241637" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24461143" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23524219" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28844193" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30793734" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24394381" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26105732" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23659733" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pacemaker or defibrillator surgery without interruption of anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20435662" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22464216" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34170841" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture in Patients on Oral Anticoagulation - Post Hoc Analysis of the ISAR-CLOSURE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860058" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34882436" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33895845" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
